Reposting this from 8/30/14 as a recap of my quick thoughts on our two new additions to management in 2014: I thought the repost was relevant due to Saturday's news that Pat Kernan is stepping down (being replaced) as President and COO effective 2/28/15. I'm not certain if we will have to wait until 2/28 to learn who his successor is, but if that successor is in line with the quality of Howard Dietrich and Ed Parsley, I will be very pleased.
Personal Thoughts on New CMO at Mast: Ed Parsley was working at Encysive Pharmaceuticals with PAH drugs when it was acquired by Pfizer in 2008. Ed became the clinical lead for successful Revatio trials while at Pfizer. Ed then moved to Aires Pharmaceutical as their CMO. Aires is then acquired by Mast this year to add promising air001 to the pipeline for potential in PAH.
Conclusion #1: Ed Parsley has been successful working with clinical drugs through approval and his companies seem to have a propensity to be acquired by larger pharmaceutical companies when he is currently employed there.
Our recent addition of Board Member Dr. Dittrich in 2014 is also very promising. Dr. Dittrich was the CMO of Sorbent Therapeutics when it was successfully acquired by Merck in 2007.
Conclusion #2: we have two new top tier employees at Mast Therapeutics that have a recent history of both clinical trial success and a history of their companies being acquired by larger pharma's when they are currently employed there.
Again, this is just a repost of thoughts from news in 2014, but I thought it might be interesting if you missed it first time around.
Have a great Sunday night everyone....and if you are located in the Northeast like me, please be careful during the storm that is barreling our way.
RR
